Literature DB >> 31808389

Anti-Cholinesterase Activity of Chalcone Derivatives: Synthesis, In Vitro Assay and Molecular Docking Study.

Florentinus D O Riswanto1, Mira S A Rawa2, Vikneswaran Murugaiyah2, Nurul H Salin3, Enade P Istyastono1, Maywan Hariono1, Habibah A Wahab2.   

Abstract

BACKGROUND: Chalcones, originated from natural product, have been broadly studied their biological activity against various proteins which at the molecular level, are responsible for the progress of the diseases in cancer (e.g. kinases), inflammation (oxidoreductases), atherosclerosis (cathepsins receptor), and diabetes (e.g. α-glucosidase).
OBJECTIVE: Here we synthesize 10 chalcone derivatives to be evaluated their in vitro enzymatic inhibition activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).
METHODS: The synthesis was carried out using Claissen-Schimdt condensation and the in vitro assay was conducted using Ellman Method.
RESULTS: Compounds 2b and 4b demonstrated as the best IC50 of 9.3 μM and 68.7 μM respectively, towards AChE and BChE inhibition. Molecular docking studies predicted that this activity might be due to the interaction of the chalcones with important amino acid residues in the binding site of AChE such as SER200 and in that of BChE, such as TRP82, SER198, TRP430, TYR440, LEU286 and VAL288.
CONCLUSION: Chalcone can be used as the scaffold for cholinesterase inhibitor, in particularly either fluorine or nitro group to be augmented at the para-position of Ring B, whereas the hydrophobic chain is necessary at the meta-position of Ring B. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Alzheimer's disease; acetylcholinesterase; butyrylcholinesterase; chalcone; docking; in vitro assay.

Year:  2021        PMID: 31808389     DOI: 10.2174/1573406415666191206095032

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  4 in total

Review 1.  Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus.

Authors:  Yustina Hartini; Bakti Saputra; Bryan Wahono; Zerlinda Auw; Friska Indayani; Lintang Adelya; Gabriel Namba; Maywan Hariono
Journal:  Results Chem       Date:  2020-12-25

2.  A study on catalytic and non-catalytic sites of H5N1 and H1N1 neuraminidase as the target for chalcone inhibitors.

Authors:  Pandu Hariyono; Jasvidianto Chriza Kotta; Christophorus Fideluno Adhipandito; Eko Aprilianto; Evan Julian Candaya; Habibah A Wahab; Maywan Hariono
Journal:  Appl Biol Chem       Date:  2021-09-17       Impact factor: 1.813

3.  Gender Differences in Demographic and Pharmacological Factors in Patients Diagnosed with Late-Onset of Alzheimer's Disease.

Authors:  Melissa J Bailey-Taylor; Nicolas Poupore; Laurie Theriot Roley; Richard L Goodwin; Brooks Mcphail; Thomas I Nathaniel
Journal:  Brain Sci       Date:  2022-01-26

4.  PyPLIF HIPPOS and Receptor Ensemble Docking Increase the Prediction Accuracy of the Structure-Based Virtual Screening Protocol Targeting Acetylcholinesterase.

Authors:  Enade P Istyastono; Florentinus Dika Octa Riswanto; Nunung Yuniarti; Vivitri D Prasasty; Sudi Mungkasi
Journal:  Molecules       Date:  2022-09-02       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.